Jeffrey P. Sharman

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Jennifer L. Crombie, Tara Graff, Lorenzo Falchi et al. · Blood · 2024 · 131 citations · Full text

Life Sciences, Immunology, Oncology +14

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

Jacob D. Soumerai, Ai Ni, Mohamed Darif et al. · The Lancet Haematology · 2019 · 67 citations · Full text

Medicine, Immunology, Oncology +16

Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study.

John C. Byrd, K. A. Blum, Jan A. Burger et al. · Journal of Clinical Oncology · 2011 · 34 citations

Medicine, Oncology, Pharmacology +16

Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.

Ranjana H. Advani, Jeffrey P. Sharman, S. M. Smith et al. · Journal of Clinical Oncology · 2010 · 32 citations

Medicine, Pharmacokinetics, Pharmacology +17

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

Laurie H. Sehn, Michael Hallek, Wojciech Jurczak et al. · Blood · 2016 · 31 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11